How Dennis Gillings took a gamble and built a $3.7bn business
This article was originally published in Scrip
Executive Summary
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
INTERVIEW: Elliott Sigal - stretching R&D dollars and leveraging data at BMS
Elliott Sigal is a winner. He came top of a December 2012 Scrip Intelligence analysis that identified the best R&D chief in the pharma industry (of recent times). Bristol-Myers Squibb’s executive vice-president and chief scientific officer beat off a challenge from several other candidates including Novartis's Mark Fishman, Amgen's Roger Perlmutter, and Merck's Peter Kim.